QUEST DIAGNOSTICS INCORPORATED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 126.6 USD | -0.32% |
|
-2.72% | -8.27% |
| Apr. 11 | John Chevedden Files an Exempt Solicitation Statement with Securities and Exchange Commission | CI |
| Apr. 05 | Quest Diagnostics Receives Shareholder Proposal from John Chevedden | CI |
Financials (USD)
| Sales 2024 * | 9.4B | Sales 2025 * | 9.71B | Capitalization | 14.1B |
|---|---|---|---|---|---|
| Net income 2024 * | 897M | Net income 2025 * | 965M | EV / Sales 2024 * | 1.89 x |
| Net Debt 2024 * | 3.7B | Net Debt 2025 * | 3.23B | EV / Sales 2025 * | 1.79 x |
| P/E ratio 2024 * |
16.3
x | P/E ratio 2025 * |
15
x | Employees | 44,000 |
| Yield 2024 * |
2.31% | Yield 2025 * |
2.39% | Free-Float | 68.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on Quest Diagnostics Incorporated
More recommendations
More press releases
More news
| 1 day | -0.35% | ||
| 1 week | -3.53% | ||
| Current month | -4.61% | ||
| 1 month | -1.01% | ||
| 3 months | -5.04% | ||
| 6 months | +2.99% | ||
| Current year | -7.91% |
1 week
126.74
130.30
1 month
126.74135.45
Current year
123.04143.63
1 year
119.59148.62
3 years
119.59174.16
5 years
73.02174.16
10 years
54.90174.16
| Managers | Title | Age | Since |
|---|---|---|---|
James Davis
CEO | Chief Executive Officer | 61 | 13-03-31 |
Sam Samad
DFI | Director of Finance/CFO | 54 | 22-07-10 |
Kristin Wallace
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Denise Morrison
BRD | Director/Board Member | 70 | 19-02-17 |
Timothy Ring
BRD | Director/Board Member | 67 | 11-12-06 |
Gail Wilensky
BRD | Director/Board Member | 80 | 96-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.84% | 215 M€ | +12.15% | - | |
| 2.17% | 2 M€ | +6.54% | ||
| 2.05% | 8 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 126.6 | -0.32% | 156 229 |
| 24-04-17 | 127 | -0.35% | 886,750 |
| 24-04-16 | 127.4 | -0.95% | 692,266 |
| 24-04-15 | 128.6 | +0.09% | 698,794 |
| 24-04-12 | 128.5 | -1.15% | 720,163 |
Delayed Quote Nyse, April 17, 2024 at 04:00 pm EDT
More quotes
Quest Diagnostics is the world's leading provider of diagnostics testing and information service for patients and health professionals. Net sales break down by activity as follows:
- testing and diagnostic services (97.3%): routine clinical testing, gene-based testing and advanced diagnostic and anatomica pathology diagnostic services;
- other (2.7%).
Calendar
2024-04-23
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
127
USD
Average target price
142.1
USD
Spread / Average Target
+11.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.91% | 14.1B | |
| +14.91% | 82.27B | |
| +11.06% | 29.43B | |
| -12.02% | 16.82B | |
| -5.09% | 15.89B | |
| -0.10% | 12.05B | |
| -29.82% | 12.01B | |
| +21.84% | 11.19B | |
| -5.74% | 11.09B | |
| +44.20% | 10.91B |
- Stock Market
- Equities
- DGX Stock
